Takeda Pharmaceuticals U.S.A. Inc.
1 Takeda Pkwy
About Takeda Pharmaceutical
Millennium Pharmaceuticals was established in 1993 as a genomics company, applying world-class molecular biology and genomic technologies to the discovery and development of new therapies in a broad spectrum of diseases. Over time we evolved into a fully integrated biopharmaceutical company.
In May 2008, Millennium was acquired by Takeda Pharmaceutical Company Limited in Japan and became known as Millennium: The Takeda Oncology Company (Millennium), a wholly-owned subsidiary of Takeda that served as the organization’s global center of excellence in oncology.
The combination of oncology resources resulted in a robust pipeline that addresses a broad range of cancers. Our focus is to improve the treatment of cancer, which gives us an important oncology mission to deliver extraordinary medicines to patients with cancer worldwide through our science, innovation and passion, toward an ultimate goal and aspiration to cure cancer.
In May 2013, the decision was made to fully integrate Millennium into the global Takeda R&D engine to maximize the resources available from the broader Takeda organization and to realize greater operational efficiencies. The R&D and G&A functions in Boston became known publically as Takeda Pharmaceuticals International Co. The oncology Commercial, Business Development and Patient Advocacy divisions continue to operate as Millennium: The Takeda Oncology Company.
At Takeda and Millennium, we want to exceed expectations in terms of progress against cancer, distinguishing ourselves within the research-based biopharmaceutical community. We’re prepared to deliver on this goal by focusing on novel or best-in-class drug candidates, and cultivating the brightest talent. This puts Takeda on an exciting path toward global oncology leadership.
We help drive and accelerate the progress that continually is being made against cancer; these advances, sometimes big breakthroughs and sometimes incremental, make a real difference in the lives of patients. We won’t be satisfied until cures are found and the threat is removed. People who battle cancer deserve no less.
Our goal also is to provide patients and people close to them with easily understandable information about the diseases our products treat, as well as other relevant information and service resources. We also provide information about our investigational drugs that are approaching or in development, our clinical trials, and what patients, caregivers and healthcare providers need to know about our assistance and access programs for any drug we currently market. We work toward our goals with the same urgency for patients that we would for our families. We strive to earn the respect and admiration of the global oncology community by delivering significant progress against cancer while living our core values.
The people and culture at Takeda and Millennium make all the difference.
Our work is more than a job. We are entrepreneurial about both our work and achieving progress. We focus on what’s important and timely decision-making.
As a site based in New England, we enjoy our local community and contribute in many ways to local business, social and environmental causes. We offer a broad range of opportunities for campus-based employees to participate. We also involve ourselves on a corporate level in matters of social responsibility.
June 12, 1781
Founder: Chobei Takeda
CEO: Christophe Weber
CMO (Medical) and CSO (Scientific): Andrew Plump
CFO: James Kehoe
Please click here for Takeda job opportunities.
Tweets by Takeda
952 articles with Takeda Pharmaceutical
On Tuesday, Takeda Pharmaceutical finally wrapped up its $62 billion acquisition of Shire plc. As the combined companies continue to merge and shape their combined roles, Chief Executive Officer Christophe Weber is already eying potential deals to offset some of the debt the company garnered.
Takeda Completes Acquisition of Shire, Becoming a Global, Values-based, R&D-Driven Biopharmaceutical Leader
− 8 months from deal announcement to deal close − Strong shareholder support with high approval rates on Takeda (89.1%) and Shire (99.8%) − Integration planning well underway
Takeda Completes Acquisition of Shire, Becoming a Global, Values-Based, R&D-Driven Biopharmaceutical Leader
8 months from deal announcement to deal close
GlaxoSmithKline, Teva, Takeda Investing in Global Sustainability Performance with the Responsible Health Initiative
Collaboration between key players in the pharmaceutical, biotechnology and healthcare fields fortifies responsible business practices and shared value within global health supply chain
1/8/2019Last year’s sole mega-deal, the acquisition of Dublin-based Shire by Japan-based Takeda Pharmaceutical is finally closed. Takeda, 237 years old, is now a top 10 international drug company.
Recursion Announces Options Exercise by Takeda and Extension of AI-enabled Drug Discovery Collaboration
From collaboration to licensing options in less than 18 months
Takeda Notes Court Sanction of the Scheme of Arrangement with Respect to the Acquisition of Shire plc
It is expected that the Scheme will become effective, and that closing of the Acquisition will take place, on January 8, 2019
Takeda Pharmaceutical Company Limited is planning to evaluate the application of recently licensed Humabodies from Crescendo for the development of novel CAR-T therapeutics.
This morning, Osaka, Japan-based Takeda struck deals with Memorial Sloan Kettering Cancer Center, Noile-Immune Biotech Inc. and Crescendo Biologics.
Takeda Announces Multiple Cell Therapy Collaborations to Advance the Company’s Novel Immuno-Oncology Portfolio
Takeda Pharmaceutical Company Limited (“Takeda”) (TSE: 4502) today announced new research collaborations in immuno-oncology (I-O), an area of key strategic focus for the company.
In writing literally hundreds of stories this year, two BioSpace writers, Alex Keown and Mark Terry, found certain stories particularly intriguing or impactful. Some of those were such big topics that they were covered over a series of stories. Looking back at 2018, here are their Top 10.
Paris-based Sanofi announced it was transferring its listing of American Depositary Shares (ADS) from the New York Stock Exchange (NYSE) to The Nasdaq Global Select Market starting end-of-day December 31, 2018. They will start trading on January 2, 2019.
ADSs Will Trade Under the Ticker Symbol “TAK”
Takeda Receives Positive CHMP Opinion for ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage IV Hodgkin Lymphoma in Combination with AVD
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for the extension of the marketing authorization of ADCETRIS
The 2019 award celebrates two leading global regenerative medicine researchers
The U.S. public apparently believes that drug prices are too high. At the same time, they seem largely opposed to government efforts to control health care costs, alternately supportive and non-supportive of efforts to eliminate the Affordable Care Act, better known as Obamacare.
Takeda Pharmaceutical Company Limited today announced the results of the shareholder votes at its Extraordinary General Meeting of Shareholders (“EGM”) regarding the recommended acquisition of Shire plc.
Although it was probably not in serious peril, shareholders of Japan’s Takeda Pharmaceutical voted to approve the acquisition of Dublin’s Shire. The deal is currently valued at $58 billion.
Seattle Genetics and Takeda Present Positive Data from Phase 3 ECHELON-2 Clinical Trial for ADCETRIS® (Brentuximab Vedotin) in Frontline Treatment of CD30-Expressing Peripheral T-Cell Lymphomas
-Data Presented in Oral Session with Simultaneous Publication in The Lancet-
Seattle Genetics and Takeda show off the impressive survival data that prompted the FDA to give approval to Adcetris for this indication.